New data from Janssen-Cilag International NV suggest that subcutaneous DARZALEX (daratumumab) quadruplet therapy could offer a longer progression free survival for patients with newly diagnosed ...

A systematic literature review identified 362 records from 67 studies across 10 countries. Results showed romosozumab significantly improved bone mineral density at 12 months in lumbar spine, total ...